Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities.

Autor: O'Donnell, Michelle M.¹ (AUTHOR), Hegarty, James W.² (AUTHOR), Healy, Brian¹ (AUTHOR), Schulz, Sarah¹ (AUTHOR), Walsh, Calum J.^1,2 (AUTHOR), Hill, Colin¹ (AUTHOR), Ross, R. Paul¹ (AUTHOR), Rea, Mary C.² (AUTHOR), Farquhar, Ronald³ (AUTHOR), Chesnel, Laurent³ (AUTHOR) lchesnel@adisotx.com

Publikováno v: Scientific Reports. 11/13/2022, Vol. 12 Issue 1, p1-13. 13p.

Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo .

Autor: Murphy CK; Research and Development, Adiso Therapeutics Inc., Concord, MA 01742, United States., O'Donnell MM; APC Microbiome Ireland, University College Cork, Cork T12 K8AF, Ireland., Hegarty JW; Teagasc Food Research Centre, Moorepark Fermoy, Cork P61 C996, Ireland., Schulz S; APC Microbiome Ireland, University College Cork, Cork T12 K8AF, Ireland., Hill C; APC Microbiome Ireland, University College Cork, Cork T12 K8AF, Ireland., Ross RP; APC Microbiome Ireland, University College Cork, Cork T12 K8AF, Ireland., Rea MC; Teagasc Food Research Centre, Moorepark Fermoy, Cork P61 C996, Ireland., Farquhar R; Executive Leadership Team, Adiso Therapeutics Inc., Concord, MA 01742, United States., Chesnel L; Research and Development, Adiso Therapeutics Inc., Concord, MA 01742, United States. lchesnel@adisotx.com.

Publikováno v: World journal of gastrointestinal pathophysiology [World J Gastrointest Pathophysiol] 2023 Aug 24; Vol. 14 (4), pp. 71-85.